CTOR Stock Analysis: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.91
0.01 (0.65%)
▲
5d:
-4.03%
30d:
+37.39%
90d:
-19.75%
BUY
HIGH Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: Feb 13, 2026
0d
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CTOR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: CTOR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1.09
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$0.68
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.91, which is considered slightly high relative to its 30-day fair value range of $0.70 to $0.93. From a valuation perspective, the stock is trading at a premium (Forward PE: 2.3) compared to its historical average (2.0). At these levels, the market is pricing in 5.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.81, while resistance sits at $0.99.
Market Sentiment: CTOR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.00 (+561.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.81, while resistance sits at $0.99.
Market Sentiment: CTOR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.00 (+561.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.70 -
$0.93
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
75.2%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 561.7% below Wall St target ($6.00)
- NEUTRAL: Trading at premium valuation - market expects 5.2% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$0.70 -
$0.93
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.81
Resistance Level
$0.99
Current Trend
Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.33
Wall Street Target
$6.00
(+561.7%)
Valuation Premium vs History
+5.2% premium
PE vs Historical
2.3 vs 2.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.2%
(market-implied from PE analysis)
1-Year Target
$0.95
(+5%)
2-Year Target
$1.00
(+11%)
3-Year Target
$1.06
(+16%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
PE COMPRESSION
$0.91
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: May 09, 2026 2:58 AM ET
Data refreshes hourly during market hours. Next update: 3:58 AM
Data refreshes hourly during market hours. Next update: 3:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$186 | 66 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$96 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$149 | 52 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 54 HOLD |